Total diet replacement
BehavioralTotal diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.
NCT Number: NCT05491005
Overweight patients with type 2 diabetes are offered a total diet replacement with the goal of weight loss and diabetes remission. Study participants are randomised to eHealth follow-up or face-to-face follow-up, but the dietary advice is the same in both groups. A healthy control group with normal glucose tolerance is examined once but is not randomised and does not receive any intervention.
Interested in participating?
Request Info20 year–70 year
All sexes
Interventional
Not applicable
Bra Liv Råslätt vårdcentral, Jönköping, Sweden
One hundred and six overweight patients with type 2 diabetes replace usual foods with total diet replacement (850 kcal/day) for 3 months with the goal of 15 kg weight loss and diabetes remission (HbA1c < 48 mmol/mol without diabetes medication). After 3 months of total diet replacement, food is reintroduced stepwise, and an individually tailored energy prescription is used to prevent weight regain. If study participants do not reach the weight loss goal at 3 months, they are recommended two additional months of total diet replacement. If weight regain occurs during the weight maintenance phase, a rescue plan with total diet replacement will be recommended. To increase the chances to maintain their lower body weight, participants will use a program specifically design for that purpose based on cognitive behavioural therapy. Total study duration is two years.
The one hundred and six participants are randomised to either the eHealth follow-up or the face-to-face follow-up. The dietary advice to achieve and maintain weight loss is the same in both groups and delivered by the same dietician, physician, and nurse but the method of follow-up differs between groups (eHealth vs face-to-face).
eHealth group:
All study information and the cognitive behavioural therapy program is given by an eHealth application in Stöd och behandling which is part of 1177.se. Participants register body weight, fasting blood glucose, and blood pressure every morning at 1177.se. Regularly a measurement of HbA1c is taken at home. Participants will have scheduled video appointments with the study dietician, study nurse or study physician.
Face-to-face group:
Participants have appointments in the medical office with the study physician/nurse/dietician. At the appointments, body weight, blood pressure and capillary blood glucose is measured. HbA1c is measured during the appointments at 0, 6, 12 and 24 months. The cognitive behavioral therapy program for the control group is identical to the program of the intervention group, but the program is delivered during the face-to-face appointments.
Healthy control group:
Fifteen healthy participants with normal glucose tolerance, stable body weight for at least one year and matched to the study participants for sex, age, and weight after one year study duration, will be examined once. These participants are not randomised and do not receive any intervention.
Outcomes:
Primary and secondary outcome measures are compared between 1) the experimental eHealth group and 2) the experimental face-to-face group. For the other pre-specified outcome measures the experimental eHealth group and the experimental face-to-face group are taken together as one group, examined twice (baseline and 12 months) and compared to the healthy control group, that is examined only once.
Long-term follow-up:
Because long term data on diabetes remission by total diet replacement are lacking, study participants will be followed after they have finished the study. Data of the national diabetes registry from participants of this study will be compared to other patients in the national diabetes registry not participating in this study but matched for age, sex and diabetes duration to the study participants.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.
All follow-up through an eHealth application and video meetings.
All follow-up through face-to-face meetings.
Time frame: 12 months
HbA1c without diabetes medication as a continuous outcome (HbA1c correction according to Tsapas et al 2020 if on diabetes medication). The outcome will be tested for non-inferiority first, with a non-inferiority margin of 8 mmol/mol; followed by a test for superiority.
Time frame: 6 and 24 months
HbA1c without diabetes medication as a continuous outcome (HbA1c correction according to Tsapas et al 2020 if on diabetes medication). The outcome will be tested for non-inferiority first, with a non-inferiority margin of 8 mmol/mol; followed by a test for superiority.
Time frame: 6, 12 and 24 months
Number of participants with HbA1c < 48 mmol/mol without diabetes medication. The outcome will be tested for non-inferiority first with a non-inferiority margin of 10 percentage points; followed by a test for superiority.
Time frame: 6, 12 and 24 months
Body weight as a continuous outcome
Time frame: 6, 12 and 24 months
Number of participants with achieved weight loss of at least 15 kg
Time frame: 24 months
Time frame: 24 months
Time frame: 24 months
Time frame: 6, 12, 24 months
Partial diabetes remission (<7.0 mol/l), complete diabetes remission (<6.1 mol/l) without diabetes medication.
Time frame: 6, 12, 24 months
Time frame: 6, 12, 24 months
Time frame: 6, 12, 24 months
Time frame: 6, 12, 24 months
Measured at the research facilities
Time frame: 6, 12, 24 months
24h monitoring
Time frame: 6, 12, 24 months
Time frame: 6, 12, 24 months
AST, ALT
Time frame: 6, 12, 24 months
Time frame: 6, 12, 24 months
Time frame: 6, 12, 24 months
Three factor eating questionnaire
Time frame: 6, 12, 24 months
Karolinska Exhaustion Disorder Scale. Minimum value 0. Maximum value 54. A higher score means a worse outcome.
Time frame: 6, 12, 24 months
The scale estimates how satisfied the participants is with different areas of life, as well as how important each area of life is. Minimum scale 0. Maximum scale 48. A higher score means a better outcome.
Time frame: 6, 12, 24 months
The questionnaire investigates the dimensions mobility, self-care, usual activities, pain and anxiety/depression. Minimum value 1. Maximum value 5. A higher score means a worse outcome. In addition, a general health score is assessed. Minimum value 0. Maximum value 100. A higher score means a better outcome. All dimension will be analysed separately, but EQ-5D-5L will also be combined to one score.
Time frame: 6, 12, 24 months
FFQ 2020 questionnaire
Time frame: 6, 12, 24 months
SF-36 questionnaire
Time frame: 6, 12, 24 months
Measured with activity tracker
Time frame: 24 months
Qualitative questions with written answers about study experience
Time frame: Yearly up to 20 years
Collected from patient journals after study completion
Time frame: Yearly up to 20 years
Collected from patient journals after study completion
Time frame: Yearly up to 20 years
Collected from patient journals after study completion
Time frame: Yearly up to 20 years
Collected from patient journals after study completion
Time frame: Yearly up to 20 years
Collected from patient journals after study completion
Time frame: Yearly up to 20 years
Collected from patient journals and registries after study completion
Time frame: 12 months
Hyperinsulinemic euglycemic clamp
Time frame: 12 months
Stepped insulin secretion test with arginine
Time frame: 12 months
Hyperinsulinemic euglycemic clamp
Time frame: 12 months
Indirect calorimetry
Time frame: 12 months
Dual-energy X-ray absorptiometry (DXA).
Time frame: 12 months
Plasma amino acids are measured during 120 minutes after a intravenous glucagon bolus
Time frame: 12 months
Plasma amino acids are measured during intravenous amino acid infusion
Time frame: 12 months
Plasma glucagon is measured during intravenous amino acid infusion
Time frame: 6, 12, 24 months
GLP-1, GIP and gherkin during the oral glucose tolerance test
Time frame: 6, 12, 24 months
Metabolomics and lipidomics analyses during the oral glucose tolerance test
Time frame: 12 months
Measured with MRI
Time frame: 12 months
Measured with MRI
Time frame: 12 months
Time frame: 12 months
RNA sequencing
Time frame: 12 months
Time frame: 6, 12 and 24 months
Only men
Time frame: 6, 12, 24 months
Only men, Erectile function subscale
Time frame: 6, 12, 24 months
Only men, International prostate symptom score
Time frame: 6, 12, 24 months
Time frame: 12 months
Spirometry
Time frame: 12 months
Spirometry
Time frame: 12 months
Spirometry
Time frame: 12 months
Spirometry
Time frame: Once between 12 and 24 months
Individual semi-structured interviews
Contact information is provided by the study sponsor or research team.
Umeå University
Other
eHealth Diabetes Remission Trial (Swedish: Remission av Typ 2 Diabetes Med hjälp av eHälsa
Acronym: eDIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06138821
Body Weight, Body Weight Changes
Boston, Massachusetts, United States
View Trial DetailsNCT07588438
Body Weight, Body Weight Changes
Asunción, Paraguay
View Trial DetailsNCT03620773
Adolescent Obesity, Bariatric Surgery Candidate
Aurora, Colorado, United States
View Trial DetailsNCT05874726
Apnea, Body Weight
Boston, Massachusetts, United States
View Trial Details